tbuckley/cabot-search huggingface dataset:
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers
Authors: Tessa Gargett, Nga T H Truong, Bryan Gardam, Wenbo Yu, Lisa M Ebert, Amy Johnson, Erica C F Yeo, Nicole L Wittwer, Gonzalo Tapia Rico, Jesikah Logan, Purany Sivaloganathan, Maria Collis, Andrew Ruszkiewicz, Michael P Brown
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies. If CAR-T cell therapy for non-hematological malignancies is to achieve the same stage of clinical development, then iterative early-phase clinical testing can add value to the clinical development process for evaluating CAR-T cell products containing different CAR designs and manufactured under differing conditions. Methods We conducted a phase 1 trial of third-generation GD2-specific CAR-T cell therapy, which has previously been tested in neuroblastoma patients. In this study, the GD2-CAR-T therapy was evaluated for the first time in metastatic melanoma patients in combination with BRAF/MEK inhibitor therapy, and as a monotherapy in patients with colorectal cancer and a patient with fibromyxoid sarcoma. Feasibility and safety were determined and persistence studies, multiplex cytokine arrays on sera and detailed immune phenotyping of the original CAR-T products, the circulating CAR-T cells, and, in select patients, the tumor-infiltrating CAR-T cells were performed. Results We demonstrate the feasibility of manufacturing CAR-T products at point of care for patients with solid cancer and show that a single intravenous infusion was well tolerated with no dose-limiting toxicities or severe adverse events. In addition, we note significant improvements in CAR-T cell immune phenotype, and expansion when a modified manufacturing procedure was adopted for the latter 6 patients recruited to this 12-patient trial. We also show evidence of CAR-T cell-mediated immune activity and in some patients expanded subsets of circulating myeloid cells after CAR-T cell therapy. Conclusions This is the first report of third-generation GD2-targeting CAR-T cells in patients with metastatic melanoma and other solid cancers such as colorectal cancer, showing feasibility, safety and immune activity, but limited clinical effect. Trial registration number ACTRN12613000198729.
Unveiling Metabolic Similarities of Entheses in Patients with Psoriasis and Psoriatic Arthritis Using Noninvasive In Vivo Molecular Imaging: Results From a Cross‐sectional Exploratory Study
Authors: Filippo Fagni, Koray Tascilar, Rita Noversa de Sousa, Sara Bayat, Lukas Sollfrank, Arnd Kleyer, Michael Sticherling, Adrian P. Regensburger, Ferdinand Knieling, Markus F. Neurath, Georg Schett, Maximilian Waldner, David Simon
Journal: Arthritis & Rheumatology (2024)

We assessed and compared molecular tissue changes at the entheses in patients with psoriasis (PsO) and psoriatic arthritis (PsA) and in healthy controls (HCs) in vivo using multispectral optoacoustic tomography (MSOT) and described their relationship with clinical and ultrasound findings of enthesitis.
Integrating Radiomics and Neural Networks for Knee Osteoarthritis Incidence Prediction
Authors: Shengfa Li, Peihua Cao, Jia Li, Tianyu Chen, Ping Luo, Guangfeng Ruan, Yan Zhang, Xiaoshuai Wang, Weiyu Han, Zhaohua Zhu, Qin Dang, Qianyi Wang, Mengdi Zhang, Qiushun Bai, Zhiyi Chai, Hao Yang, Haowei Chen, Mingze Tang, Arafat Akbar, Alexander Tack, David J. Hunter, Changhai Ding
Journal: Arthritis & Rheumatology (2024)

Accurately predicting knee osteoarthritis (KOA) is essential for early detection and personalized treatment. We aimed to develop and test a magnetic resonance imaging (MRI)-based joint space (JS) radiomic model (RM) to predict radiographic KOA incidence through neural networks by integrating meniscus and femorotibial cartilage radiomic features.
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study
Authors: Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer, Amer M. Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P. Bystrom, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Stein, Vinod Pullarkat, Ibrahim Aldoss, Daniel J. DeAngelo, Donna S. Neuberg, Richard M. Stone, Sylvain Garciaz, Brian Ball, Maximilian Stahl
Journal: American Journal of Hematology (2024)
American College of Rheumatology White Paper: The Effects of Climate Change on Rheumatic Conditions—An Evolving Landscape and a Path Forward
Authors: Paul F. Dellaripa, Lily H. Sung, Paul A. Bain, Cristina Lanata, Ashira Blazer, Frederick W. Miller, Candace H. Feldman
Journal: Arthritis & Rheumatology (2024)

Increases in global temperatures and extreme weather events associated with climate change have complex yet poorly understood detrimental impacts on human health. We reviewed the current published literature on climate change-related effects and rheumatic conditions.
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
Authors: Cristina A. Tentori, Lin P. Zhao, Benedetta Tinterri, Kathryn E. Strange, Katharina Zoldan, Konstantinos Dimopoulos, Xingmin Feng, Elena Riva, Benjamin Lim, Yannick Simoni, Vidhya Murthy, Madeline J. Hayes, Antonella Poloni, Eric Padron, Bruno A. Cardoso, Michael Cross, Susann Winter, Aida Santaolalla, Bhavisha A. Patel, Emma M. Groarke, Daniel H. Wiseman, Katy Jones, Lauren Jamieson, Charles Manogaran, Naval Daver, Laura Gallur, Wendy Ingram, P. Brent Ferrell, Katja Sockel, Nicolas Dulphy, Nicolas Chapuis, Anne S. Kubasch, Astrid M. Olsnes, Austin Kulasekararaj, Hugues De Lavellade, Wolfgang Kern, Mieke Van Hemelrijck, Dominique Bonnet, Theresia M. Westers, Sylvie Freeman, Uta Oelschlaegel, David Valcarcel, Marco G. Raddi, Kirsten Grønbæk, Michaela Fontenay, Sanam Loghavi, Valeria Santini, Antonio M. Almeida, Jonathan M. Irish, David A. Sallman, Neal S. Young, Arjan A. van de Loosdrecht, Lionel Adès, Matteo G. Della Porta, Catherine Cargo, Uwe Platzbecker, Shahram Kordasti
Journal: HemaSphere (2024)

Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during MDS evolution. Nonetheless, immunotherapy for MDS has not experienced breakthroughs seen in other malignancies, partly attributable to the absence of an immune classification that could stratify patients toward optimally targeted immunotherapeutic approaches. A pivotal obstacle to establishing "immune classes" among MDS patients is the absence of validated accepted immune panels suitable for routine application in clinical laboratories. In response, we formed International Integrative Innovative Immunology for MDS (i4MDS), a consortium of multidisciplinary experts, and created the following recommendations for standardized methodologies to monitor immune responses in MDS. A central goal of i4MDS is the development of an immune score that could be incorporated into current clinical risk stratification models. This position paper first consolidates current knowledge on MDS immunology. Subsequently, in collaboration with clinical and laboratory specialists, we introduce flow cytometry panels and cytokine assays, meticulously devised for clinical laboratories, aiming to monitor the immune status of MDS patients, evaluating both immune fitness and identifying potential immune "risk factors." By amalgamating this immunological characterization data and molecular data, we aim to enhance patient stratification, identify predictive markers for treatment responsiveness, and accelerate the development of systems immunology tools and innovative immunotherapies.
Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study
Authors: Milena Falcaro, Kate Soldan, Busani Ndlela, Peter Sasieni
Journal: BMJ (2024)

Abstract Objectives To replicate previous analyses on the effectiveness of the English human papillomavirus (HPV) vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) using 12 additional months of follow-up, and to investigate effectiveness across levels of socioeconomic deprivation. Design Observational study. Setting England, UK. Participants Women aged 20-64 years resident in England between January 2006 and June 2020 including 29 968 with a diagnosis of cervical cancer and 335 228 with a diagnosis of CIN3. In England, HPV vaccination was introduced nationally in 2008 and was offered routinely to girls aged 12-13 years, with catch-up campaigns during 2008-10 targeting older teenagers aged &lt;19 years. Main outcome measures Incidence of invasive cervical cancer and CIN3. Results In England, 29 968 women aged 20-64 years received a diagnosis of cervical cancer and 335 228 a diagnosis of CIN3 between 1 January 2006 and 30 June 2020. In the birth cohort of women offered vaccination routinely at age 12-13 years, adjusted age standardised incidence rates of cervical cancer and CIN3 in the additional 12 months of follow-up (1 July 2019 to 30 June 2020) were, respectively, 83.9% (95% confidence interval (CI) 63.8% to 92.8%) and 94.3% (92.6% to 95.7%) lower than in the reference cohort of women who were never offered HPV vaccination. By mid-2020, HPV vaccination had prevented an estimated 687 (95% CI 556 to 819) cervical cancers and 23 192 (22 163 to 24 220) CIN3s. The highest rates remained among women living in the most deprived areas, but the HPV vaccination programme had a large effect in all five levels of deprivation. In women offered catch-up vaccination, CIN3 rates decreased more in those from the least deprived areas than from the most deprived areas (reductions of 40.6% v 29.6% and 72.8% v 67.7% for women offered vaccination at age 16-18 and 14-16, respectively). The strong downward gradient in cervical cancer incidence from high to low deprivation in the reference unvaccinated group was no longer present among those offered the vaccine. Conclusions The high effectiveness of the national HPV vaccination programme previously seen in England continued during the additional 12 months of follow-up. HPV vaccination was associated with a substantially reduced incidence of cervical cancer and CIN3 across all five deprivation groups, especially in women offered routine vaccination.
Issue 4 - Impact of air pollution on COVID-19 mortality and morbidity: An epidemiological and mechanistic review
Authors: Hasan Bayram, Nur Konyalilar, Muge Akpinar Elci, Hadi Rajabi, G Tuşe Aksoy, Deniz Mortazavi, Özgecan Kayalar, Öner Dikensoy, Luis Taborda-Barata, Giovanni Viegi
Journal: Pulmonology (2024)

Air pollution is a major global environment and health concern. Recent studies have suggested an association between air pollution and COVID-19 mortality and morbidity. In this context, a close association between increased levels of air pollutants such as particulate matter ≤2.5 to 10 µM, ozone and nitrogen dioxide and SARS-CoV-2 infection, hospital admissions and mortality due to COVID 19 has been reported. Air pollutants can make individuals more susceptible to SARS-CoV-2 infection by inducing the expression of proteins such as angiotensin converting enzyme (ACE)2 and transmembrane protease, serine 2 (TMPRSS2) that are required for viral entry into the host cell, while causing impairment in the host defence system by damaging the epithelial barrier, muco-ciliary clearance, inhibiting the antiviral response and causing immune dysregulation. The aim of this review is to report the epidemiological evidence on impact of air pollutants on COVID 19 in an up-to-date manner, as well as to provide insights on in vivo and in vitro mechanisms.
Advancing Care for AA Amyloidosis with Biomarker-Based Staging
Authors: Helen J. Lachmann
Journal: Journal of the American Society of Nephrology (2024)

National Amyloidosis Centre, University College London, and Royal Free Hospital London NHS Foundation Trust, London, United Kingdom Correspondence: Prof. Helen J. Lachmann, email: [email protected] See related article, "Development and Validation of Staging Systems for AA Amyloidosis," on pages 782–794.
Small Transjugular Intrahepatic Portosystemic Shunt Plus Variceal Embolization for Gastric Varices: A Multicenter Cohort Study
Authors: Yifu Xia, Jun Tie, Guangchuan Wang, Yuzheng Zhuge, Hao Wu, Xiaoli Zhu, Hui Xue, Jiao Xu, Feng Zhang, Lianhui Zhao, Guangjun Huang, Mingyan Zhang, Bo Wei, Peijie Li, Ze Wang, Wei Wu, Chao Chen, Shifeng Yang, Yicheng Han, Chengwei Tang, Chunqing Zhang
Journal: Clinical Gastroenterology and Hepatology (2024)

The effect of transjugular intrahepatic portosystemic shunt (TIPS) plus variceal embolization for treating gastric varices (GVs) remains controversial. This nationwide multicenter cohort study aimed to evaluate whether adding variceal embolization to a small diameter (8-mm) TIPS could reduce the rebleeding incidence in patients with different types of GVs. This retrospective cohort study involved 629 patients who underwent 8-mm TIPS for gastric varices at 7 medical centers. The primary endpoint was all-cause rebleeding, and the secondary endpoints included overt hepatic encephalopathy (OHE) and all-cause mortality. A total of 629 patients were included. Among them, 429 (68.2%) had gastroesophageal varices type 1 (GOV1), 145 (23.1%) had gastroesophageal varices type 2 (GOV2), and 55 (8.7%) had isolated gastric varices type 1 (IGV1). In the entire cohort, adjunctive embolization reduced rebleeding (6.2% vs 13.6%; P = .005) and OHE (31.0% vs 39.4%; P = .02) compared with TIPS alone. However, no significant differences were found in mortality (12.0% vs 9.7%; P = .42). In patients with GOV2 and IGV1, TIPS plus variceal embolization reduced both rebleeding (GOV2: 7.8% vs 25.1%; P = .01; IGV1: 5.6% vs 30.8%; P = .03) and OHE (GOV2: 31.8% vs 51.5%; P = .008; IGV1: 11.6% vs 38.5%; P = .04). However, in patients with GOV1, adjunctive embolization did not reduce rebleeding (5.9% vs 8.7%; P = .37) or OHE (33.1% vs 35.3%; P = .60). Compared with TIPS alone, 8-mm TIPS plus variceal embolization reduced rebleeding and OHE in patients with GOV2 and IGV1. These findings suggest that patients with GOV2 and IGV1, rather than GOV1, could benefit from embolization with TIPS.
Duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy in Ontario, Canada: a population-based cohort study
Authors: Arlinda Ruco, Rahim Moineddin, Rinku Sutradhar, Jill Tinmouth, Qing Li, Linda Rabeneck, M Elisabetta Del Giudice, Catherine Dubé, Nancy N Baxter
Journal: The Lancet. Gastroenterology & hepatology (2024)
Association of Ultra-processed Food and Unprocessed or Minimally Processed Food Consumption With Bowel Habits Among U.S. Adults
Authors: Chun-Han Lo, Longgang Zhao, Euridice Martinez Steele, Chun-Wei Pan, Jeffrey K. Lee, Xuehong Zhang, Harminder Singh, N. Jewel Samadder
Journal: Clinical Gastroenterology and Hepatology (2024)
Mechanisms for Mitoprotection and Amelioration of Acute Kidney Injury Risk
Authors: Guanshi Zhang, Kumar Sharma
Journal: Journal of the American Society of Nephrology (2024)

Center for Precision Medicine, Long School of Medicine, University of Texas Health San Antonio, and Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, Texas Correspondence: Dr. Kumar Sharma, email: [email protected] See related article, "Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31," on pages 681–695.
Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke
Authors: Gang Li, Yapeng Lin, Jie Yang, Craig S Anderson, Chen Chen, Feifeng Liu, Laurent Billot, Qiang Li, Xiaoying Chen, Xiaoqiu Liu, Xinwen Ren, Chunfang Zhang, Ping Xu, Lijun Wu, Feng Wang, Daijun Qiu, Mei Jiang, Yiqian Peng, Chaohui Li, Yiyang Huang, Xiaohui Zhao, Jiye Liang, Yao Wang, Xiangjun Wu, Xiaoyun Xu, Guofang Chen, Dongya Huang, Yue Zhang, Lian Zuo, Guozhao Ma, Yumei Yang, Junjie Hao, Xiahong Xu, Xinli Xiong, Yueyu Tang, Yijia Guo, Jianping Yu, Shuping Li, Song He, Fengkai Mao, Quandan Tan, Song Tan, Nengwei Yu, Ruxiang Xu, Mingwei Sun, Binghu Li, Jiang Guo, Leibo Liu, Hueiming Liu, Menglu Ouyang, Lei Si, Hisatomi Arima, Philip M Bath, Gary A Ford, Thompson Robinson, Else Charlotte Sandset, Jeffrey L Saver, Nikola Sprigg, H Bart van der Worp, Lili Song
Journal: New England Journal of Medicine (2024)

Treatment of acute stroke, before a distinction can be made between ischemic and hemorrhagic types, is challenging. Whether very early blood-pressure control in the ambulance improves outcomes among patients with undifferentiated acute stroke is uncertain.
Commentary on “Comparing the oncologic outcomes of local tumor destruction vs. local tumor excision vs. partial nephrectomy in T1a solid renal masses: a population-based cohort study from the SEER database”
Authors: Saisai Jing, Jianke Ma, Yupeng Di, Jiazhao Song
Journal: International Journal of Surgery (2024)

aDepartment of Oncology, Affiliated Cixi Hospital, Wenzhou Medical University, Cixi, Zhejiang 315300, P. R. China bDepartment of Radiotherapy, Air Force Medical Center, Beijing 100142, P. R. China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding Author Address: Department of Radiotherapy, Air Force Medical Center, Beijing 100142, P. R. China, Tel: +86 15610760073. E-mail address: [email protected] (J. Song). *Corresponding Author Address: Department of Radiotherapy, Air Force Medical Center, Beijing 100142, P. R. China, Tel: +86 13581915870. E-mail address: [email protected] (Y. Di). *Corresponding Author Address: Department of Oncology, Affiliated Cixi Hospital, Wenzhou Medical University, Cixi, Zhejiang 315300, P. R. China, Tel: +86 15158190037. E-mail address: [email protected] (S. Jing). This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/
γδ T cell profiling in a cohort of preterm infants reveals elevated frequencies of <i>CD83</i>+ γδ T cells in sepsis
Authors: Ximena León-Lara, Alina S. Fichtner, Maike Willers, Tao Yang, Katharina Schaper, Lennart Riemann, Jennifer Schöning, Anna Harms, Vicente Almeida, Anja Schimrock, Anika Janssen, Laura Ospina-Quintero, Constantin von Kaisenberg, Reinhold Förster, Matthias Eberl, Manuela F. Richter, Sabine Pirr, Dorothee Viemann, Sarina Ravens
Journal: The Journal of Experimental Medicine (2024)

Preterm infants are at high risk of developing neonatal sepsis. γδ T cells are thought to be an important set of effector cells in neonates. Here, γδ T cells were investigated in a longitudinal cohort of preterm neonates using next-generation sequencing, flow cytometry, and functional assays. During the first year of life, the Vγ9Vδ2 T cell subset showed dynamic phenotypic changes and elevated levels of fetal-derived Vγ9Vδ2 T cells were evident in infants with sepsis. Single-cell transcriptomics identified HLA-DRhiCD83+ γδ T cells in neonatal sepsis, which expressed genes related to antigen presentation. In vitro assays showed that CD83 was expressed on activated Vγ9Vδ2 T cells in preterm and term neonates, but not in adults. In contrast, activation of adult Vγ9Vδ2 T cells enhanced CD86 expression, which was presumably the key receptor to induce CD4 T cell proliferation. Together, we provide a map of the maturation of γδ T cells after preterm birth and highlight their phenotypic diversity in infections.
Physician and Artificial Intelligence Chatbot Responses to Cancer Questions From Social Media
Authors: David Chen, Rod Parsa, Andrew Hope, Breffni Hannon, Ernie Mak, Lawson Eng, Fei-Fei Liu, Nazanin Fallah-Rad, Ann M. Heesters, Srinivas Raman
Journal: JAMA Oncology (2024)

Artificial intelligence (AI) chatbots pose the opportunity to draft template responses to patient questions. However, the ability of chatbots to generate responses based on domain-specific knowledge of cancer remains to be tested.
A de novo TLR7 gain-of-function mutation causing severe monogenic lupus in an infant
Authors: Jarmila Stremenova Spegarova, Praisoody Sinnappurajar, Dalila Al Julandani, Rokas Navickas, Helen Griffin, Manisha Ahuja, Angela Grainger, Katie Livingstone, Gillian I. Rice, Fraser Sutherland, Corinne Hayes, Simon Parke, Lewis Pang, Marion R. Roderick, Mary Slatter, Yanick Crow, Athimalaipet V. Ramanan, Sophie Hambleton
Journal: Journal of Clinical Investigation (2024)
Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair
Authors: Dominik Saul, Madison L Doolittle, Jennifer L Rowsey, Mitchell N Froemming, Robyn L Kosinsky, Stephanie J Vos, Ming Ruan, Nathan K LeBrasseur, Abhishek Chandra, Robert J Pignolo, João F Passos, Joshua N Farr, David G Monroe, Sundeep Khosla
Journal: Journal of Clinical Investigation (2024)

Cells expressing features of senescence, including upregulation of p21 and p16, appear transiently following tissue injury, yet the properties of these cells or how they contrast with age-induced senescent cells remains unclear. Here, we used skeletal injury as a model and identified the rapid appearance following fracture of p21+ cells expressing senescence markers, mainly as osteochondroprogenitors (OCHs) and neutrophils. Targeted genetic clearance of p21+ cells suppressed senescence-associated signatures within the fracture callus and accelerated fracture healing. By contrast, p21+ cell clearance did not alter bone loss due to aging; conversely, p16+ cell clearance, known to alleviate skeletal aging, did not affect fracture healing. Following fracture, p21+ neutrophils were enriched in signaling pathways known to induce paracrine stromal senescence, while p21+ OCHs were highly enriched in senescence-associated secretory phenotype factors known to impair bone formation. Further analysis revealed an injury-specific stem cell-like OCH subset that was p21+ and highly inflammatory, with a similar inflammatory mesenchymal population (fibro-adipogenic progenitors) evident following muscle injury. Thus, intercommunicating senescent-like neutrophils and mesenchymal progenitor cells were key regulators of tissue repair in bone and potentially across tissues. Moreover, our findings established contextual roles of p21+ vs p16+ senescent/senescent-like cells that may be leveraged for therapeutic opportunities.
Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized-controlled ELAN Trial
Authors: Roman Rohner, Markus Kneihsl, Martina B. Goeldlin, Arsany Hakim, Mattia Branca, Stefanie Abend, Waldo Valenzuela Pinilla, Sabine Fenzl, Beata Rezny-Kasprzak, Daniel Strbian, Sven Trelle, Maurizio Paciaroni, Götz Thomalla, Patrik Michel, Krassen Nedeltchev, Thomas Gattringer, Else C. Sandset, Leo Bonati, Diana Aguiar de Sousa, P.N. Sylaja, George Ntaios, Masatoshi Koga, Zuzana Gdovinova, Robin Lemmens, Natan M. Bornstein, Peter Kelly, Mira Katan, Thomas Horvath, Jesse Dawson, Urs Fischer
Journal: Circulation (2024)

Whether hemorrhagic transformation (HT) modifies the treatment effect of early compared with late initiation of direct oral anticoagulation in people with ischemic stroke and atrial fibrillation is unknown.